New Horizon’s Sales Surge as China Promotes Early Cancer Detection
Company’s first-mover advantage in at-home colorectal screening and China’s focus on early detection have turbocharged sales, though valuation remains frothy Key takeaways: New Horizon’s first-half revenues jumped more than fourfold,…
RELATED ARTICLES
-
New Horizon Health launches probe into disputed sales figures
6606.HK -
Hutchmed scores U.S. success with cancer drug, but profits still dip
HCM.US 0013.HK
-
Goldwind’s profit tumbles as China sales start to deflate
2208.HK 002202.SHE
- Bayzed joins IPO quest as medical rivalry heats up
-
Kindstar Globalgene finds bargain in solid tumor testing acquisition
9960.HK
-
Junshi narrows its losses but delivers no cure for share price woes
1877.HK 688180.SHG
